Dyslipidemia in Chronic Kidney Disease

慢性肾脏病中的血脂异常

• 批准号: 7113747
• 负责人: JEFFREY M SALAND
• 金额: $ 12.85万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7113747
• 关键词: adolescence (12-20); atherosclerotic plaque; cardiovascular disorder; chronic disease /disorder; clinical research; dietary lipid; genetic polymorphism; human subject; hyperlipidemia; insulin sensitivity /resistance; kidney disorder; lipid metabolism; lipoprotein disorder; magnetic resonance imaging; pathologic process; patient oriented research; triglycerides; young adult human (21-34)

DESCRIPTION (provided by applicant): Goal: To provide Jeffrey M. Saland, MD with a mentored program for patient-oriented research resulting in his development as an independent physician-scientist with expertise in both nephrology and lipoprotein metabolism. Candidate: Dr. Saland is junior faculty in Pediatric Nephrology since July 2002. He completed the first year of the Mount Sinai School of Medicine K30 program while developing his interest in dyslipidemia and cardiovascular disease (CVD) associated with chronic kidney disease (CKD). Dr. Saland will obtain advanced training in lipoprotein physiology and vascular biology through graduate level courses at the Columbia University Institute of Human Nutrition. He will complete a Master's Degree in the Mount Sinai K30 program and gain knowledge of genomic investigation by teaming with experienced collaborators. Research: Approximately 8 million people in the U.S. have CKD. These individuals, particularly those with severe CKD, suffer premature and accelerated CVD. While dyslipidemia is common in this setting, its origins and pathological role remain unclear. This project will test the hypothesis that children and young adults with CKD develop impairment in the normal pathways of triglyceride-rich lipoprotein metabolism as part of an atherogenic metabolic syndrome that includes insulin resistance. Several approaches will be used to test this hypothesis: 1) Measure the rate of post-prandial triglyceride metabolism while assessing the influences of insulin resistance and severity of CKD; 2) Assess the utility of vessel wall MRI to measure sub-clinical atherosclerotic plaque and its relation to dyslipidemia in young people with CKD; 3) Extract useful measures from the array of techniques used in this project and develop them for future research or clinical purposes. Environment: Dr. Saland's development will be guided by experienced mentors, advanced by organized coursework in lipoprotein physiology and the conduct of clinical research, and supported with protected research time and designated space. Dr. Saland will uniquely benefit from the combined excellence of two General Clinical Research Centers operating in the dynamic academic environments of Mount Sinai, Columbia University, and an active New York lipid and vascular disease research community

描述（由申请人提供）： 目标：为医学博士的杰弗里·萨兰德（Jeffrey M. Saland）提供针对患者研究的指导计划，从而导致他作为独立的医生 - 科学家的发展，具有肾脏病和脂蛋白代谢方面的专业知识。候选人：萨兰博士自2002年7月以来一直是小儿肾脏病的初级教职员工。他完成了西奈山医学学院K30计划的第一年，同时又培养了他对与慢性肾脏病（CKD）相关的血脂异常和心血管疾病（CVD）的兴趣。 Saland博士将通过哥伦比亚大学人类营养研究所的研究生课程获得脂蛋白生理学和血管生物学的高级培训。他将完成西奈山K30计划的硕士学位，并通过与经验丰富的合作者合作获得基因组研究的知识。研究：美国约有800万人患有CKD。这些人，特别是患有严重CKD的人，遭受过早且加速的CVD。尽管血脂异常在这种情况下很常见，但其起源和病理作用尚不清楚。该项目将检验以下假设：患有CKD的儿童和年轻人在富含甘油三酸酯的脂蛋白代谢的正常途径中会受到损害，这是包括胰岛素抵抗的动脉粥样硬化代谢综合征的一部分。将使用几种方法来检验这一假设：1）衡量后甘油三酸酯代谢的速率，同时评估CKD的胰岛素抵抗和严重程度的影响； 2）评估血管壁MRI的效用，以测量CKD年轻人的临界动脉粥样硬化斑块及其与血脂异常的关系； 3）从本项目中使用的一系列技术中提取有用的措施，并为将来的研究或临床目的而开发它们。环境：Saland博士的发展将由经验丰富的导师指导，以脂蛋白生理学的有组织课程和临床研究的进行，并得到受保护的研究时间和指定空间的支持。萨兰德博士将在西奈山，哥伦比亚大学的动态学术环境中以及一个活跃的纽约脂质和血管疾病研究社区中的两个一般临床研究中心的卓越综合中受益